← Back to Clinical Trials
Recruiting NCT04109846

Pregnancy and Developmental Outcomes After Transfer of Reportedly Aneuploid or Mosaic Embryos

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Aneuploidy
Sponsor Stanford University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 300
Sex FEMALE
Min Age 18 Years
Max Age 55 Years
Start Date 2019-04-11
Completion 2035-04
Interventions
Non-euploid embryo transferEuploid Transfer

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

To determine how often embryos reported to be abnormal by preimplantation genetic testing result in liveborn infants. To evaluate whether the pregnancies that result from these embryos are higher risk for complications and whether the resulting babies have higher risk for health or developmental issues in the first five years after birth.

Eligibility Criteria

Inclusion Criteria: * Available aneuploid or mosaic embryos * No other acceptable embryos available * Willing to travel to Stanford for treatment * English language fluency Exclusion Criteria: * Use of international donor eggs or sperm not tested according to FDA guidelines. * Living outside the United States * Embryos with Triploidy are not eligible for transfer in this protocol

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}